Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Taletrectinib is an inhibitor of c-Ros oncogene 1 (ROS1), tropomyosin-related kinase A (TrkA), and TrkC (IC50s = 0.207, 0.622, and 0.98 nM, respectively).1 It is selective for these kinases over TrkB (IC50 = 2.28 nM). Talectrectinib (1-10,000 nM) reduces the viability of JFCR-165, JFCR-168, and MGH193-1B patient-derived CD74-ROS1 fusion protein-positive non-small cell lung cancer (NSCLC) cells. In vivo, talectrectinib (25-100 mg/kg) reduces tumor volume in Ba/F3 mouse xenograft models expressing CD74-ROS1 wild-type fusion proteins or crizotinib-resistant CD74-ROS1G2032R mutant fusion proteins.
WARNING This product is not for human or veterinary use.
1. The new-